The role of immunotherapy in in vitro fertilization: a guideline

Practice Committee of the American Society for Reproductive Medicine, ASRM@asrm.org, American Society for Reproductive Medicine, Birmingham, Alabama, USA

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Adjuvant immunotherapy treatments in in vitro fertilization (IVF) aim to improve the outcome of assisted reproductive technology (ART) in both the general ART population as well as subgroups such as patients with recurrent miscarriage or implantation failure. The purpose of this guideline is to evaluate the role of immunomodulating therapy in ART. Unfortunately, many of the evaluated therapies lack robust evidence from well-designed adequately powered randomized controlled trials to support their use. Immunotherapies reviewed in the present document are either not associated with improved live-birth outcome in IVF or have been insufficiently studied to make definitive recommendations.

Original languageEnglish (US)
Pages (from-to)387-400
Number of pages14
JournalFertility and Sterility
Volume110
Issue number3
DOIs
StatePublished - Aug 1 2018

Fingerprint

Assisted Reproductive Techniques
Fertilization in Vitro
Immunotherapy
Guidelines
Habitual Abortion
Live Birth
Therapeutics
Randomized Controlled Trials
Population

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Practice Committee of the American Society for Reproductive Medicine, ASRM@asrm.org, American Society for Reproductive Medicine, Birmingham, Alabama, USA (2018). The role of immunotherapy in in vitro fertilization: a guideline. Fertility and Sterility, 110(3), 387-400. https://doi.org/10.1016/j.fertnstert.2018.05.009

The role of immunotherapy in in vitro fertilization : a guideline. / Practice Committee of the American Society for Reproductive Medicine, ASRM@asrm.org, American Society for Reproductive Medicine, Birmingham, Alabama, USA.

In: Fertility and Sterility, Vol. 110, No. 3, 01.08.2018, p. 387-400.

Research output: Contribution to journalArticle

Practice Committee of the American Society for Reproductive Medicine, ASRM@asrm.org, American Society for Reproductive Medicine, Birmingham, Alabama, USA 2018, 'The role of immunotherapy in in vitro fertilization: a guideline', Fertility and Sterility, vol. 110, no. 3, pp. 387-400. https://doi.org/10.1016/j.fertnstert.2018.05.009
Practice Committee of the American Society for Reproductive Medicine, ASRM@asrm.org, American Society for Reproductive Medicine, Birmingham, Alabama, USA. The role of immunotherapy in in vitro fertilization: a guideline. Fertility and Sterility. 2018 Aug 1;110(3):387-400. https://doi.org/10.1016/j.fertnstert.2018.05.009
Practice Committee of the American Society for Reproductive Medicine, ASRM@asrm.org, American Society for Reproductive Medicine, Birmingham, Alabama, USA. / The role of immunotherapy in in vitro fertilization : a guideline. In: Fertility and Sterility. 2018 ; Vol. 110, No. 3. pp. 387-400.
@article{549877b948a34b7d812fc83e1d935879,
title = "The role of immunotherapy in in vitro fertilization: a guideline",
abstract = "Adjuvant immunotherapy treatments in in vitro fertilization (IVF) aim to improve the outcome of assisted reproductive technology (ART) in both the general ART population as well as subgroups such as patients with recurrent miscarriage or implantation failure. The purpose of this guideline is to evaluate the role of immunomodulating therapy in ART. Unfortunately, many of the evaluated therapies lack robust evidence from well-designed adequately powered randomized controlled trials to support their use. Immunotherapies reviewed in the present document are either not associated with improved live-birth outcome in IVF or have been insufficiently studied to make definitive recommendations.",
author = "{Practice Committee of the American Society for Reproductive Medicine, ASRM@asrm.org, American Society for Reproductive Medicine, Birmingham, Alabama, USA} and Alan Penzias and Kristin Bendikson and Samantha Butts and Christos Coutifaris and Tommaso Falcone and Susan Gitlin and Clarisa Gracia and Karl Hansen and Jindal, {Sangita K.} and Jennifer Mersereau and Randall Odem and Robert Rebar and Richard Reindollar and Mitchell Rosen and Jay Sandlow and Peter Schlegel and Dale Stovall and Michael Vernon",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.fertnstert.2018.05.009",
language = "English (US)",
volume = "110",
pages = "387--400",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The role of immunotherapy in in vitro fertilization

T2 - a guideline

AU - Practice Committee of the American Society for Reproductive Medicine, ASRM@asrm.org, American Society for Reproductive Medicine, Birmingham, Alabama, USA

AU - Penzias, Alan

AU - Bendikson, Kristin

AU - Butts, Samantha

AU - Coutifaris, Christos

AU - Falcone, Tommaso

AU - Gitlin, Susan

AU - Gracia, Clarisa

AU - Hansen, Karl

AU - Jindal, Sangita K.

AU - Mersereau, Jennifer

AU - Odem, Randall

AU - Rebar, Robert

AU - Reindollar, Richard

AU - Rosen, Mitchell

AU - Sandlow, Jay

AU - Schlegel, Peter

AU - Stovall, Dale

AU - Vernon, Michael

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Adjuvant immunotherapy treatments in in vitro fertilization (IVF) aim to improve the outcome of assisted reproductive technology (ART) in both the general ART population as well as subgroups such as patients with recurrent miscarriage or implantation failure. The purpose of this guideline is to evaluate the role of immunomodulating therapy in ART. Unfortunately, many of the evaluated therapies lack robust evidence from well-designed adequately powered randomized controlled trials to support their use. Immunotherapies reviewed in the present document are either not associated with improved live-birth outcome in IVF or have been insufficiently studied to make definitive recommendations.

AB - Adjuvant immunotherapy treatments in in vitro fertilization (IVF) aim to improve the outcome of assisted reproductive technology (ART) in both the general ART population as well as subgroups such as patients with recurrent miscarriage or implantation failure. The purpose of this guideline is to evaluate the role of immunomodulating therapy in ART. Unfortunately, many of the evaluated therapies lack robust evidence from well-designed adequately powered randomized controlled trials to support their use. Immunotherapies reviewed in the present document are either not associated with improved live-birth outcome in IVF or have been insufficiently studied to make definitive recommendations.

UR - http://www.scopus.com/inward/record.url?scp=85051120646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051120646&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2018.05.009

DO - 10.1016/j.fertnstert.2018.05.009

M3 - Article

C2 - 30098685

AN - SCOPUS:85051120646

VL - 110

SP - 387

EP - 400

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 3

ER -